TABLE 2.

Follow-up of the 26 Evaluable Patients

Variable	A (N = 26)
Number cycles received, No. (%)
1	3 (12%)
2	2 (8%)
3	2 (8%)
4	6 (23%)
5	3 (12%)
6	10 (38%)
Progression status, No. (%)
Progression-free	4 (15%)
Progression	22 (85%)
Follow-up status, No. (%)
Alive	2 (8%)
Dead	24 (92%)
Reason end treatment, No. (%)
Completed study per protocol	10 (38%)
Refused further treatment	1 (4%)
Adverse reactions	4 (15%)
Disease progression	5 (19%)
Alternate treatment	1 (4%)
Other medical problems	1 (4%)
Died on study	4 (15%)
Confirmed response
PR	16 (62%)
Stable	6 (23%)
No post baseline assessment	4 (15%)